Real-time Estimate
Cboe BZX
02:16:35 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
32.15
USD
|
-2.52%
|
|
-9.89%
|
+51.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
221.4
|
377.3
|
234.3
|
27.67
|
775.2
|
1,329
|
-
|
-
|
Enterprise Value (EV)
1 |
221.4
|
377.3
|
234.3
|
27.67
|
435.6
|
690.8
|
995.3
|
1,253
|
P/E ratio
|
-3.12
x
|
-5.18
x
|
-4.75
x
|
-0.45
x
|
-0.44
x
|
-7.88
x
|
-9.21
x
|
-7.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
12.5
x
|
11.9
x
|
875
x
|
227
x
|
300
x
|
6,643
x
|
EV / Revenue
|
-
|
-
|
12.5
x
|
11.9
x
|
492
x
|
118
x
|
225
x
|
6,263
x
|
EV / EBITDA
|
-2.77
x
|
-4.69
x
|
-
|
-
|
-1.8
x
|
-4.43
x
|
-5.47
x
|
-
|
EV / FCF
|
-3.3
x
|
-4.71
x
|
-4.32
x
|
-
|
-4.36
x
|
-3.75
x
|
-7.21
x
|
-8.35
x
|
FCF Yield
|
-30.3%
|
-21.2%
|
-23.2%
|
-
|
-22.9%
|
-26.6%
|
-13.9%
|
-12%
|
Price to Book
|
3.7
x
|
2.7
x
|
2.79
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,159
|
1,917
|
1,973
|
2,460
|
36,021
|
40,283
|
-
|
-
|
Reference price
2 |
191.0
|
196.8
|
118.8
|
11.25
|
21.52
|
32.98
|
32.98
|
32.98
|
Announcement Date
|
2/24/20
|
3/18/21
|
3/8/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
18.74
|
2.329
|
0.886
|
5.843
|
4.429
|
0.2
|
EBITDA
1 |
-79.92
|
-80.48
|
-
|
-
|
-241.6
|
-155.8
|
-182
|
-
|
EBIT
1 |
-80.33
|
-81.48
|
-65.65
|
-84.78
|
-242.3
|
-191
|
-194.8
|
-233
|
Operating Margin
|
-
|
-
|
-350.33%
|
-3,640.23%
|
-27,347.97%
|
-3,268.86%
|
-4,397.69%
|
-116,477.3%
|
Earnings before Tax (EBT)
1 |
-78.25
|
-80.89
|
-65.66
|
-83.95
|
-338.8
|
-172.8
|
-191.9
|
-233.2
|
Net income
1 |
-78.25
|
-80.89
|
-65.8
|
-83.82
|
-338.8
|
-174.1
|
-192.6
|
-227.5
|
Net margin
|
-
|
-
|
-351.14%
|
-3,598.75%
|
-38,238.15%
|
-2,979.61%
|
-4,348.97%
|
-113,747.3%
|
EPS
2 |
-61.25
|
-38.00
|
-25.00
|
-24.75
|
-49.12
|
-4.185
|
-3.580
|
-4.230
|
Free Cash Flow
1 |
-67.18
|
-80.06
|
-54.29
|
-
|
-99.91
|
-184
|
-138
|
-150
|
FCF margin
|
-
|
-
|
-289.71%
|
-
|
-11,276.52%
|
-3,149.14%
|
-3,116.13%
|
-75,000%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
3/18/21
|
3/8/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.644
|
1.362
|
0.625
|
0.174
|
0.168
|
0.198
|
0.688
|
-
|
-
|
-
|
2.857
|
-
|
3
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.44
|
-24.44
|
-22.42
|
-18.76
|
-19.16
|
-18.81
|
-159.2
|
-32.95
|
-45.91
|
-47.77
|
-43.87
|
-47.56
|
-45.9
|
-50
|
-53
|
Operating Margin
|
-560.98%
|
-1,794.49%
|
-3,587.68%
|
-10,778.74%
|
-11,405.95%
|
-9,497.98%
|
-23,146.22%
|
-
|
-
|
-
|
-1,535.54%
|
-
|
-1,530.09%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.42
|
-24.44
|
-22.31
|
-18.44
|
-18.78
|
-18.46
|
-217.1
|
-40.1
|
-63.18
|
-43.82
|
-41.16
|
-45.51
|
-48.22
|
-50
|
-53
|
Net income
1 |
-20.45
|
-24.44
|
-22.32
|
-18.23
|
-18.82
|
-18.42
|
-217.1
|
-40.11
|
-63.18
|
-43.86
|
-41.75
|
-45.52
|
-47.92
|
-50
|
-53
|
Net margin
|
-561.09%
|
-1,794.13%
|
-3,571.68%
|
-10,479.31%
|
-11,203.57%
|
-9,304.04%
|
-31,552.47%
|
-
|
-
|
-
|
-1,461.36%
|
-
|
-1,597.28%
|
-
|
-
|
EPS
2 |
-7.750
|
-9.250
|
-6.750
|
-4.750
|
-4.500
|
-5.000
|
-56.75
|
-9.340
|
-4.050
|
-1.200
|
-1.022
|
-1.033
|
-0.9600
|
-0.7850
|
-0.9750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/8/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/11/23
|
8/11/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
340
|
638
|
333
|
76
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-67.2
|
-80.1
|
-54.3
|
-
|
-99.9
|
-184
|
-138
|
-150
|
ROE (net income / shareholders' equity)
|
-123%
|
-80.9%
|
-58.8%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-97.3%
|
-66.1%
|
-48.5%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
80.46
|
122.4
|
135.8
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
51.70
|
72.90
|
42.50
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.49
|
4.28
|
0.57
|
0.04
|
-
|
2
|
1.17
|
2
|
Capex / Sales
|
-
|
-
|
3.06%
|
1.63%
|
-
|
34.23%
|
26.34%
|
1,000%
|
Announcement Date
|
2/24/20
|
3/18/21
|
3/8/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
32.98
USD Average target price
45
USD Spread / Average Target +36.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +51.12% | 1.33B | | +9.81% | 118B | | +10.02% | 106B | | -11.93% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.67% | 15.97B | | +6.19% | 14.03B | | +14.70% | 11.67B |
Bio Therapeutic Drugs
|